{"page":{"totalFilteredElements":90},"studies":[{"active":true,"description":"Clinical Research Platform For Molecular Testing, Treatment, Quality Of Life And Outcome Of Patients With Esophageal, Gastric Or Gastroesophageal Junction Cancer Requiring Palliative Systemic Therapy (SAPHIR)<br />","eudractNumber":null,"id":5701,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio1","name":"Karzinom der Speiseröhre (Oesophaguskarzinom, inkl. gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04290806","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2019-12-19T10:45:37+01:00","shortTitle":"SAPHIR","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<p>Prospective Non-interventional Study to Collect Real-world Clinical and Patient-reported Outcome Data in Ovarian Cancer Patients Eligible for First-line Platinum-based Chemotherapy and Intended for BRCA/HRD Testing </p>","eudractNumber":null,"id":7907,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[{"name":"BRCA (BReast CAncer)","id":"mt_204"}],"nctNumber":"NCT04830709","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-13T13:30:32+01:00","shortTitle":"SCOUT-1","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A non-interventional study of selinexor (Nexpovio) in combination with bortezomib and dexamethasone (SVd) in patients with relapsed or refractory multiple myeloma (R/RMM) - SEATTLE -","eudractNumber":null,"id":11163,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym1","name":"Plasmozytom (Multiples Myelom)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-01T14:17:05+01:00","shortTitle":"SEATTLE","therapeutical":false,"therapyLines":[{"id":"tl_4","name":"> Drittlinie"}]},{"active":true,"description":"Systematische Erfassung und Einbeziehung von Patientinnen:pr&#228;ferenzen* in individuelle Entscheidungsfindung und aggregierte Leitlinienempfehlungen","eudractNumber":null,"id":11462,"indications":[{"id":"bru","name":"Brustkrebs (Mammakarzinom)"},{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn2","name":"Gebärmutterhalskrebs (Zervixkarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-07-30T13:44:15+02:00","shortTitle":"SEP-SDM-LL","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Klinische Forschungsplattform zur Behandlung von Eierstock-, Eileiter-, prim&#228;rem Bauchfell- und Geb&#228;rmutterschleimhautkrebs und deren Folgen","eudractNumber":null,"id":7358,"indications":[{"id":"gyn","name":"Bösartige Gynäkologische Tumoren (Gebärmutter, Eileiter etc.)"},{"id":"gyn1","name":"Gebärmutterkrebs (Uteruskarzinom)"},{"id":"gyn3","name":"Eierstockkrebs (Ovarialkarzinom)"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT05129969","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-12-09T11:11:23+01:00","shortTitle":"SMARAGD","therapeutical":false,"therapyLines":[]},{"active":true,"description":"Studien-, Dokumentations- und Qualit&#228;tszentrum der Deutschen Gesellschaft f&#252;r Allgemein- und Viszeralchirurgie","eudractNumber":null,"id":7997,"indications":[{"id":"gio","name":"Bösartige Erkrankungen des oberen Verdauungstraktes (Oesophagus, Magen, gastrooesophagealer Übergang)"},{"id":"gio2","name":"Karzinom des gastrooesophagealen Übergangs"},{"id":"gio3","name":"Magenkarzinom"},{"id":"giu","name":"Bösartige Erkrankungen des unteren Verdauungstraktes (Darm, Leber/Gallenblase, Pankreas)"},{"id":"giu1","name":"Karzinome des Dünn- und Dickdarms (Kolon, Rektum, Anus)"},{"id":"giu3","name":"Bauchspeicheldrüsenkrebs (Pankreaskarzinom)"},{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2012-01-01T09:16:52+01:00","shortTitle":"StuDoQ_Kolon_Pankreas_Schilddrüse","therapeutical":false,"therapyLines":[]},{"active":true,"description":"<div>Register und Biomaterialdatenbank f&#252;r reifzellige systemische T-Zell Lymphome (T-NHL) der German Lymphoma Alliance (GLA) und der Ostdeutschen Studiengruppe H&#228;matologie und Onkologie (OSHO)</div><div><br /></div><div>DRKS00030561</div>","eudractNumber":null,"id":8286,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym3","name":"Non-Hodgkin Lymphome (inkl. Chron. Lymphat. Leukämie, CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2021-07-14T13:56:45+02:00","shortTitle":"T-NHL Register (OSHO & GLA)","therapeutical":false,"therapyLines":[]},{"active":true,"description":"In der klinischen Studie TelePeriOP wird untersucht, ob der gezielte Einsatz von Telemedizin in Verbindung mit einem Clinical Decision Support Tool (CDS Tool) und K&#252;nstlicher Intelligenz (KI) die Qualit&#228;t der pr&#228;operativen Versorgung von Patientinnen und Patienten verbessern kann. Das Hauptziel besteht darin unn&#246;tige Vor-Ort-Termine sowie Anreise- und Wartezeiten f&#252;r Patientinnen und Patienten zu reduzieren.<div><br /></div><div>DRKS00036500</div>","eudractNumber":null,"id":12239,"indications":[{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2026-04-20T13:47:49+02:00","shortTitle":"Tele-PeriOP","therapeutical":false,"therapyLines":[]},{"active":true,"description":"A prospective, single-arm, multi-centre, blinded, observational, diagnostic accuracy study with a diagnostic medical product.<div><b>CHIRURGISCHE STUDIE</b><br /></div>","eudractNumber":null,"id":9145,"indications":[{"id":"sch","name":"Schilddrüsenkarzinom"},{"id":"nen","name":"Bösartige Tumoren der Nebenniere"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":"NCT04845867","phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2024-02-05T12:41:27+01:00","shortTitle":"Thyroid HEmorrhage DetectOr Study (HEDOS)","therapeutical":true,"therapyLines":[]},{"active":true,"description":"A prospective, non interventional study of tivozanib monotherapy as first-line therapy for patients with advanced renal cell carcinoma and with favorable or intermediate IMDC risk","eudractNumber":null,"id":11560,"indications":[{"id":"uro","name":"Urogenitale Tumoren (Niere, ableitende Harnwege, Hoden)"},{"id":"uro1","name":"Nierenzellkarzinom"},{"id":"lym","name":"Lymphome inkl. Morbus Hodgkin, Multiples Myelom und Chronisch Lymphatischer Leukämie (CLL)"},{"id":"lym4","name":"Weitere"}],"mutations":[],"nctNumber":null,"phase":{"id":"ph_2","name":"Anwendungsbeobachtung"},"recruitmentStart":"2025-08-01T09:28:53+02:00","shortTitle":"Tivoli","therapeutical":false,"therapyLines":[]}]}